Pharmaceutical research company Pharmaxis (ASX: PXS) today announced that its non-executive director Dr Simon Buckingham will retire at the conclusion of his current term at the 2018 annual general meeting, to be held on 22 November 2018.
Dr Buckingham joined the Pharmaxis Board in July 2012 and has served as a non-executive director for two terms of three years each, a critical time which has seen the Company repositioned as a drug developer focussed on inflammatory and fibrotic diseases.
Pharmaxis Chairman Malcolm McComas said, “Simon’s significant career experience in drug development, commercialisation and partnering with large pharma companies has been immensely valuable to Pharmaxis as we reorganized the business and then negotiated important partnerships with Chiesi and Boehringer Ingelheim. We recognise his considerable contribution as a director over a sustained period and wish him well as he moves into other areas.”
Dr Buckingham intends to direct his time towards early stage private companies, not-for-profit foundations and advisory opportunities. He has agreed to consult to Pharmaxis to provide assistance with current partnering discussions including the Company’s LOXL2 program.
PXS Price at posting:
30.5¢ Sentiment: None Disclosure: Not Held
